$71.20
00.00%
Last update: 8:00 PM
15 minutes delayed
Comments
Loading...
Sector
Healthcare
Region
US
AUM
264.20M
Fund Score
Invesco Biotechnology & Genome ETF (ARCA:PBE) Quotes, Forecast and News Summary
Invesco Biotechnology & Genome ETF (ARCA: PBE) stock price, news, charts, stock research, profile.
| Open | - |
| High | - |
| 52 Wk High | $72.72 |
| AUM | 264.20M |
| Dividend | $0.06 |
| Ex-Div Date | Jun 24, 2024 |
| Volume | - |
| Market Cap | $26.28B |
| Mgmt Fee | 0.5% |
| P/E Ratio | 28.60 |
| Prev. Close | $71.20 |
| Low | - |
| 52 Wk Low | $52.47 |
| Shares Out | 4.04M |
| Yield | 0.09% |
| Div. Freq | Quarterly |
| Avg. Volume Daily | 12.08K |
| Beta | 0.81 |
| Avg. Expense Ratio | NA% |
| P/B Ratio | 3.79 |
Recent News
FAQ
How do I buy Invesco Biotechnology & Genome ETF (PBE) stock?
You can purchase shares of Invesco Biotechnology & Genome ETF (ARCA:PBE) through any online brokerage.
Who are Invesco Biotechnology & Genome ETF (PBE) competitors?
There are no as such competitors for Invesco Biotechnology & Genome ETF.
What is the forecast, or price target, for Invesco Biotechnology & Genome ETF (PBE) stock?
There is no analysis for Invesco Biotechnology & Genome ETF to provide a consensus price target.
What is the current price for Invesco Biotechnology & Genome ETF (PBE)?
The stock price for Invesco Biotechnology & Genome ETF (ARCA: PBE) is $71.1984 last updated September 18, 2024 at 8:00 PM EDT.
Does Invesco Biotechnology & Genome ETF (PBE) pay a dividend?
A quarterly cash dividend of 0.00 per share of Class A Common Stock. The quarterly cash dividend was payable on September 28, 2018 to stockholders of record on September 24, 2018.
When is Invesco Biotechnology & Genome ETF (ARCA:PBE) reporting earnings?
Invesco Biotechnology & Genome ETF does not have any upcoming earnings scheduled.
Is Invesco Biotechnology & Genome ETF (PBE) going to split?
There is no upcoming split for Invesco Biotechnology & Genome ETF.
ETF Details
| Sector | Healthcare |
| Category | High Performer-Mid Growth |
| Investment Style | Mid Cap Growth |
| Fund Inception | Jun 23, 2005 |
| Managers | Tony Seisser Pratik Doshi Peter Hubbard Michael Jeanette |
| Definition | This Equity Fund Portfolio contains majority of stocks with strong financial performance and average growth potential |
Investment Policy
The Fund generally will invest at least 90% of its total assets in securities that comprise the Underlying Index. The Underlying Index is composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, and are companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| GILD | Gilead Sciences Inc | 5.48% |
| ILMN | Illumina Inc - Common | 5.37% |
| INCY | Incyte Corp. | 5.32% |
| BMRN | Biomarin Pharmaceutica... | 5.09% |
| VRTX | Vertex Pharmaceuticals... | 5.05% |
| AMGN | Amgen Inc. | 4.98% |
| REGN | Regeneron Pharmaceutic... | 4.97% |
| NBIX | Neurocrine Biosciences... | 4.51% |
| IONS | Ionis Pharmaceuticals ... | 3.24% |
| HALO | Halozyme Therapeutics ... | 3.17% |